Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization.
angiogenesis
anti-VEGF
bevacizumab
equine umbilical vein endothelial cells
Journal
Veterinary sciences
ISSN: 2306-7381
Titre abrégé: Vet Sci
Pays: Switzerland
ID NLM: 101680127
Informations de publication
Date de publication:
26 Oct 2023
26 Oct 2023
Historique:
received:
31
08
2023
revised:
06
10
2023
accepted:
22
10
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to determine the effect of bevacizumab on equine umbilical vein endothelial cells (EqUVEC). EqUVECs were harvested from umbilical cords of clinically healthy horses and exposed to different concentrations (1, 2, 4, 6, 8 mg/mL) of bevacizumab (Avastin
Identifiants
pubmed: 37999456
pii: vetsci10110632
doi: 10.3390/vetsci10110632
pmc: PMC10675369
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Wound Repair Regen. 2016 Nov;24(6):966-980
pubmed: 27681311
Biomedicines. 2017 Jun 21;5(2):
pubmed: 28635679
Clin Cancer Res. 2002 Jun;8(6):1974-83
pubmed: 12060643
J Ocul Pharmacol Ther. 2015 Oct;31(8):487-90
pubmed: 26114378
Circ Res. 2020 Jul 3;127(2):310-329
pubmed: 32833569
Ophthalmic Plast Reconstr Surg. 2012 Mar-Apr;28(2):85-9
pubmed: 22186988
Retina. 2006 Mar;26(3):352-4
pubmed: 16508438
J Clin Endocrinol Metab. 2011 Dec;96(12):E1973-81
pubmed: 21994955
Invest Ophthalmol Vis Sci. 1998 Jan;39(1):18-22
pubmed: 9430540
Invest New Drugs. 2014 Oct;32(5):851-9
pubmed: 24994097
Annu Rev Med. 2006;57:1-18
pubmed: 16409133
BMC Vet Res. 2018 Sep 3;14(1):266
pubmed: 30176852
Int J Mol Sci. 2021 Apr 05;22(7):
pubmed: 33916438
PLoS One. 2018 May 15;13(5):e0197223
pubmed: 29763436
Am J Ophthalmol. 2006 Jul;142(1):1-9
pubmed: 16815245
Biomed Pharmacother. 2018 Nov;107:1056-1063
pubmed: 30257317
Equine Vet J. 1998 Sep;30(5):366-72
pubmed: 9758092
Anat Histol Embryol. 2020 Sep;49(5):656-678
pubmed: 32639627
Vet Ophthalmol. 2021 Sep;24(5):554-568
pubmed: 34487608
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1375-82
pubmed: 19415316
PLoS One. 2020 Jul 28;15(7):e0232565
pubmed: 32722676
Res Vet Sci. 2019 Jun;124:233-238
pubmed: 30933891
J Appl Toxicol. 2017 Dec;37(12):1359-1369
pubmed: 28383141
Vet J. 2017 May;223:48-54
pubmed: 28671071
Cornea. 2013 Jul;32(7):998-1001
pubmed: 23538634
Exp Ther Med. 2022 Jul 05;24(3):555
pubmed: 35978926
J Am Vet Med Assoc. 1977 Jan 15;170(2):202-3
pubmed: 833045
Cornea. 2012 Mar;31(3):322-34
pubmed: 22157572
Front Pharmacol. 2018 Aug 31;9:978
pubmed: 30233367
J Ocul Pharmacol Ther. 2012 Dec;28(6):647-9
pubmed: 22900896
Sci Rep. 2020 Jul 14;10(1):11568
pubmed: 32665552
Nat Protoc. 2007;2(3):481-5
pubmed: 17406610
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Int J Pharm. 2022 Sep 25;625:122081
pubmed: 35934166
Biomedicines. 2019 May 16;7(2):
pubmed: 31100863
Ann Pharmacother. 2007 Apr;41(4):614-25
pubmed: 17355998
Int J Biol Macromol. 2022 Nov 30;221:1428-1438
pubmed: 36122781
Res Vet Sci. 2012 Jun;92(3):471-7
pubmed: 21492887
Angiogenesis. 2014 Jul;17(3):471-94
pubmed: 24482243
Br J Ophthalmol. 2009 Jun;93(6):837-8
pubmed: 19471005
Cancers (Basel). 2022 Jan 21;14(3):
pubmed: 35158807
Inflamm Res. 2010 Sep;59(9):689-98
pubmed: 20237827